Get the Stockscreener App
86.09
8.46%
-7.96
After Hours:
86.09
Glaukos Corporation stock is traded at $86.09, with a volume of 4.83M.
It is down -8.46% in the last 24 hours and down -16.65% over the past month.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
See More
Previous Close:
$94.05
Open:
$93.5
24h Volume:
4.83M
Relative Volume:
4.67
Market Cap:
$4.92B
Revenue:
$360.35M
Net Income/Loss:
$-149.57M
P/E Ratio:
-29.08
EPS:
-2.96
Net Cash Flow:
$-81.27M
1W Performance:
-8.78%
1M Performance:
-16.65%
6M Performance:
-44.97%
1Y Performance:
-26.53%
1-Day Range:
$83.47
$94.81
1-Week Range:
$83.47
$97.76
52-Week Range:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Name
Glaukos Corporation
Sector
Industry
Phone
949-367-9600
Address
1 GLAUKOS WAY, ALISO VIEJO, CA
Compare GKOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
86.09 | 5.37B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-11-24 | Upgrade | Citigroup | Neutral → Buy |
| Dec-06-24 | Initiated | UBS | Buy |
| Dec-02-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-24 | Downgrade | Citigroup | Buy → Neutral |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-21-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-28-23 | Initiated | Truist | Buy |
| Nov-08-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-07-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-19-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-04-22 | Initiated | Needham | Buy |
| Jul-12-22 | Upgrade | Stifel | Hold → Buy |
| Feb-03-22 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-19-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jan-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Jul-26-21 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jul-20-21 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jul-14-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-14-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-08-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-16-20 | Upgrade | Citigroup | Sell → Neutral |
| Dec-09-20 | Initiated | Oppenheimer | Perform |
| Nov-17-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-15-20 | Initiated | Jefferies | Hold |
| Mar-05-20 | Initiated | Citigroup | Sell |
| Feb-28-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-20 | Upgrade | Berenberg | Hold → Buy |
| Dec-12-19 | Downgrade | Wells Fargo | Outperform → Underperform |
| Sep-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Mar-08-19 | Initiated | BTIG Research | Neutral |
| Aug-30-18 | Initiated | Berenberg | Hold |
| Aug-29-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-03-18 | Reiterated | Stifel | Hold |
| Jun-21-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-13-18 | Downgrade | Stifel | Buy → Hold |
| Mar-01-18 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-02-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-06-17 | Upgrade | Stifel | Hold → Buy |
| Oct-27-16 | Initiated | Wells Fargo | Outperform |
View All
Glaukos Corporation Stock (GKOS) Latest News
Glaukos Corp. Reports Record Growth Amid Challenges - TipRanks
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised - TradingView
What is the risk reward ratio of investing in Glaukos Corporation stockSmart Portfolio Watchlist To Watch Now - jammulinksnews.com
Mizuho lowers Glaukos stock price target to $130 on mixed outlook - Investing.com India
Glaukos price target raised to $118 from $117 at BTIG - TipRanks
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $115 to $130 - 富途牛牛
BTIG Adjusts Price Target for Glaukos (GKOS) Amid Sales Performance - GuruFocus
Glaukos (GKOS) Price Target Cut by Mizuho Amid Portfolio Concerns - GuruFocus
Glaukos price target lowered to $130 from $150 at Mizuho - TipRanks
Glaukos Corp's Q2 2025: Unraveling Key Contradictions in iDose Reimbursement, Reimplantation Timelines, and Growth Expectations - AInvest
Glaukos Corporation's 2025 Q2 Earnings: A Breakout Moment for MIGS and Dropless Innovation - AInvest
Glaukos Corporation Reports Strong Q2 2025 Growth - TipRanks
Glaukos Corp (GKOS): A High-Growth Play in Interventional Glaucoma Amid Regulatory and Market Headwinds - AInvest
Glaukos Announces Second Quarter 2025 Financial Results - BioSpace
Earnings call transcript: Glaukos Corp beats Q2 2025 earnings estimates, stock dips - Investing.com
Glaukos shares fall as revenue beat overshadowed by guidance concerns - Investing.com South Africa
Glaukos Reports Record Q2 Sales, Raises 2025 Guidance - TipRanks
Press Release: Glaukos Announces Second Quarter 2025 Financial Results - 富途牛牛
Glaukos Corp earnings beat by $0.02, revenue topped estimates - Investing.com
Short Term Charts Align With Long Term Uptrend in Glaukos CorporationSecure Capital Picks With Upside Potential Tracked - metal.it
What analysts say about Glaukos Corporation stock outlookConsistent Gain Investment Strategies Emerge - metal.it
Glaukos Corporation Approaches Psychological Resistance LevelMarket Surge Signal for Swing Traders Triggered - metal.it
Resistance Break Could Fuel Glaukos Corporation RallyExit Ready Momentum Stock Watchlist Expanded - metal.it
Glaukos Corp (GKOS) Q2 2025 Earnings Report Preview: What To Look For - Yahoo Finance
AI Indicators Detect Buy Opportunity in Glaukos CorporationMarket Surge Signal for Swing Traders Triggered - beatles.ru
Why Glaukos Corporation stock attracts strong analyst attentionLow Risk Swing Trade Opportunities Identified - metal.it
How Glaukos Corporation stock performs during market volatilityStrong Buy With Technical Confidence Supported - metal.it
What are analysts’ price targets for Glaukos Corporation in the next 12 monthsGet timely alerts on market opportunities - jammulinksnews.com
What markets is MBIO expanding into Is Glaukos Corporation stock a good long term investment optionCapitalize on market momentum for maximum gains - jammulinksnews.com
How strong is Glaukos Corporation company’s balance sheetFree Stock Market Trend Analysis - jammulinksnews.com
What are the technical indicators suggesting about Glaukos CorporationBuild wealth steadily with smart trading - jammulinksnews.com
What is the dividend policy of Glaukos Corporation stockAchieve consistent profits with proven methods - jammulinksnews.com
Intrinsic Value of Glaukos Corporation Stock: Is It Undervalued or OvervaluedFree VIP Investment Strategies - metal.it
Should I hold or sell Glaukos Corporation stock in 2025Exceptional financial outcomes - jammulinksnews.com
What is Glaukos Corporation company’s growth strategyGet exclusive access to premium stock research - jammulinksnews.com
Published on: 2025-07-28 00:53:34 - jammulinksnews.com
What are Glaukos Corporation company’s key revenue driversDiscover the fastest growing stocks today - jammulinksnews.com
Is Glaukos Corporation a good long term investmentUnprecedented market success - PrintWeekIndia
What analysts say about Glaukos Corporation stockExplosive earning power - PrintWeekIndia
Should I buy Glaukos Corporation stock before earningsHigh-yield investments - jammulinksnews.com
Will Glaukos Corporation stock split in the near futureFree Capital Growth Strategies - jammulinksnews.com
Glaukos Corporation Stock Analysis and ForecastOutstanding capital returns - Autocar Professional
Glaukos Corporation Stock (GKOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):